Tucked inside a 3,000-page national defense bill signed into law last month is a set of new regulations that could upend the way local biotech companies do business. The Biosecure Act, as it is known, ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Boston CEOs point to a rise in funding rounds and M&A deals in late 2025 as evidence that biotech companies are learning to ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...